

Early Medications Cut Postablation Arrhythmias

BY SHERRY BOSCHERT
San Francisco Bureau

SAN FRANCISCO — Giving antiarrhythmic medications in the first 6 weeks after ablation for atrial fibrillation reduced the rate of clinically significant arrhythmias and the need for cardioversion or hospitalization in a study of 110 patients.

The findings of the Antiarrhythmics After Ablation of Atrial Fibrillation (5A) study provide the first evidence to support the common practice of prescribing antiarrhythmics to reduce arrhythmias that frequently occur after ablation, and were contrary to what the investigators expected, Dr. Jean-Francois Roux said at the annual meeting of the Heart Rhythm Society. Dr. Roux said he has no association with companies that make the medications studied.

The 5A trial was terminated early, after data on 110 of a planned 160 patients showed significant benefits from the postprocedure antiarrhythmics.

The trial was terminated early, after data on 110 out of a planned 160 patients showed significant benefits from the postprocedure antiarrhythmic drugs.

Of the 110 patients in the nonblinded study of patients scheduled to undergo ablation, 53 were randomized to start antiarrhythmia therapy the night of the procedure, using propafenone or flecainide for patients with structural heart disease, or dofetilide or sotalol if they had heart disease. The other 57 patients received only atrioventricular nodal blocking agents after ablation.

Nine patients (17%) in the antiarrhythmics group and 23 (40%) in the control group developed clinically significant atrial arrhythmias or could not tolerate the medications, reported Dr. Roux of the University of Pennsylvania, Philadelphia, and his associates. Significant arrhythmias were defined as atrial fibrillation lasting longer than 24 hours, arrhythmias requiring initiating or changing antiarrhythmic medication, or arrhythmia-related hospitalizations or electrical cardioversions.

Patients were monitored by transtelephonic devices for 4 weeks following ablation and seen 6 weeks after the procedure. The patients' mean age was 55 years, and 71% were male. Baseline characteristics were similar between groups, with an average left atrial size of 4.2 cm, normal left ventricular ejection fractions, and prior atrial fibrillation lasting an average of 71 months in the medication group and 81 months in the no-medication group. Antiarrhythmic therapy had been used before ablation by 93%-94% of patients. A quarter of each group had undergone previous atrial ablation.

Three of the patients randomized to antiarrhythmics during the study stopped therapy because of side effects including

rash, headaches, and severe fatigue.

Using just the "hard" end points of arrhythmias lasting longer than 24 hours or cardioversion or hospitalization for arrhythmia, rates still were significantly lower in the treated group (6 patients, or 11%) compared with the control group (15 patients, or 26%), he said.

Physicians tend to think of ablation and antiarrhythmic drug therapy as separate treatments, but "there can be synergies between the two," Dr. Roux said. Even some

patients who hadn't responded to antiarrhythmic therapy before ablation had protective effects against postablation arrhythmias with drug therapy, he said.

A previous study suggested that about 75% of physicians empirically prescribe antiarrhythmic therapy after ablation, and the rest do not.

Before the 5A study, physicians at Dr. Roux's institution were similarly divided in this practice. "After the study, in our group, especially among electrophysiologists,

everyone now will put patients on drugs for that 6-week period" after ablation, he said.

Investigators will continue to follow patients for 6 and 12 months to see how the 6-week postablation therapy affects long-term arrhythmia rates.

The study excluded patients who had been treated with amiodarone within 3 months prior to ablation. A separate study is comparing postablation treatment using amiodarone or dronedarone. ■

REGISTER NOW: WWW.RHEUMATOLOGYNEWSPERSPECTIVES.COM

Rheumatology News® AND  SKIN DISEASE EDUCATION FOUNDATION PRESENT

EARN UP TO
11 Credits
of CME

A continuing medical education conference

PERSPECTIVES IN RHEUMATIC DISEASES: MEETING THE CLINICAL CHALLENGE

DECEMBER 6-7, 2008 • HILTON FORT LAUDERDALE BEACH RESORT • FORT LAUDERDALE, FLORIDA

CHAIR

Daniel E. Furst, MD

Carl M. Pearson Professor of Medicine
Department of Medicine, Division of Rheumatology
David Geffen School of Medicine at the University
of California, Los Angeles (UCLA)

CO-CHAIR

Kenneth B. Gordon, MD

Head, Division of Dermatology
Evanston Northwestern Healthcare
Northwestern University Feinberg
School of Medicine, Chicago

CLINICAL HIGHLIGHTS

- **Autoimmunity Unbound: New Insights Into the Pathogenesis of Rheumatoid Arthritis**
Daniel E. Furst, MD
- **What's Ahead: New Therapies for the Treatment of Rheumatoid Arthritis**
Tore K. Kvien, University of Oslo, Past President EULAR 2005-2007
- **New Frontiers: Therapeutic Options in Juvenile Idiopathic Arthritis**
Charles H. Spencer, MD, Nationwide Children's Hospital/Ohio State University
- **MRI in Rheumatology**
Norman B. Gaylis, MD, Private Practice, University of Miami
- **Assessing Cardiac Complications in Connective Tissue Diseases**
David Edmundowicz, MD, University of Pittsburgh Medical Center
- **New Advances in the Treatment Options in SLE**
Susan Manzi, MD, MPH, University of Pittsburgh School of Medicine
- **Autoimmune Threats to Kidney Function**
Jonathan Ashley Jefferson, MD, MRCP, University of Washington
- **Clinical Manifestations and Complications of Systemic Scleroderma**
Daniel E. Furst, MD
- **Gout: What's Ahead in Disease Management**
Robert L. Wortmann, MD, Dartmouth-Hitchcock Medical Center
- **New Paradigms in Managing and Treating Ankylosing Spondylitis**
Tore K. Kvien, University of Oslo, Past President EULAR 2005-2007
- **Crohn's Disease and Ulcerative Colitis: Challenges of Inflammatory Bowel Disease**
Sunanda V. Kane, MD, Mayo Clinic College of Medicine
- **Panel Discussion: Collaborative Care of Patients with Immunologic-Based Diseases: A Rheumatology/Dermatology Perspective**
Daniel E. Furst, MD, Moderator, Kenneth B. Gordon, MD, Christopher T. Ritchlin, MD

DERMATOLOGY ESSENTIALS FOR THE RHEUMATOLOGIST

- **More Than Skin Deep: Understanding and Managing the Patient With Psoriasis**
Kenneth B. Gordon, MD
- **Therapeutic Advances in the Treatment of Psoriatic Arthritis**
Christopher T. Ritchlin, MD, University of Rochester School of Medicine and Dentistry
- **Rashes, Erythema, and Spots: Common Skin Disorders**
Michael D. Sharp, MD, Rush University Medical Center
- **Weird and Worrisome: Uncommon Skin Diseases**
Francisco Kerdel, MD, University of Miami

PROGRAM OVERVIEW

New treatment modalities are being developed in rheumatology based on scientific research breakthroughs in immunology, cytokines, T lymphocytes, B lymphocytes, as well as genetic studies that may result in gene therapies. Rheumatologists and other health care professionals need comprehensive knowledge of the latest developments and techniques in diagnosing and treating rheumatic disorders to ensure the highest standards of patient care. Rheumatologists need to have an understanding of dermatologic co-morbidities that often appear in their patients.

TARGET AUDIENCE

This continuing medical education conference is designed for rheumatologists, nurse practitioners, and physician assistants.

*Program subject to change.

TUITION	Early Bird	After 10/6/2008
Physicians	\$450	\$495
Residents/NPs/PAs	\$300	\$325

ACCOMMODATIONS

Hilton Fort Lauderdale Beach Resort
Fort Lauderdale, Florida

1 (954) 414-2222: Mention *Rheumatology News Perspectives in Rheumatic Diseases* group to receive the special rate of \$239 plus tax.

LEARNING OBJECTIVES

- At the conclusion of this conference, participants will be able to:
- Identify the recent advances in the diagnosis, management, and treatment of rheumatic diseases
 - Discuss the link between rheumatoid arthritis and inflammatory bowel diseases
 - Apply the most current information concerning the pathophysiology of rheumatic disorders to patient care plans
 - Recognize and differentiate common as well as rare skin diseases relevant to rheumatic diseases

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Elsevier Office of Continuing Medical Education (EOCME) and Skin Disease Education Foundation (SDEF). The EOCME is accredited by the ACCME to provide continuing medical education (CME) for physicians.

AMA PRA CREDIT DESIGNATION STATEMENT

The EOCME designates this educational activity for a maximum of 11 *AMA PRA Category 1 Credit(s)*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Jointly sponsored by



WWW.RHEUMATOLOGYNEWSPERSPECTIVES.COM PHONE: (973) 290-8200 FAX: (973) 290-8250